Summary: In 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30 kg/m²) from the pooled STEP-HFpEF trials, semaglutide 2.4 mg…
Browsing: Obesity & Weight Management
Evidence summaries for obesity and weight management, including lifestyle trials, pharmacotherapy, bariatric/metabolic outcomes, cardiometabolic risk, and long-term safety.
A randomized crossover trial in 75 young adults found acute sucralose raised hypothalamic blood flow and, versus sucrose, increased hunger, with no hunger difference versus water. PICO summary and expert commentary.
A 3-month randomised controlled trial found that a 10-hour time-restricted eating window did not alter mitochondrial bioenergetics in blood cells of adults at high type 2 diabetes risk. PICO summary and expert commentary.
A 2-year cluster RCT in India found a family-based, health-worker-delivered programme cut adult body weight by an adjusted 2.61 kg versus enhanced usual care. PICO summary and expert commentary.
A small mechanistic randomized trial found once-daily oral semaglutide 50 mg cut ad libitum energy intake by 39.2 percentage points versus placebo and reduced body weight, with no change in gastric emptying. PICO summary and expert commentary.
STEP 10 phase 3 RCT: once-weekly semaglutide 2.4 mg cut bodyweight by 13.9% and drove reversion to normoglycaemia in adults with obesity and prediabetes. PICO summary and expert commentary.
Pooled subgroup analysis of STEP-HFpEF and STEP-HFpEF-DM finds once-weekly semaglutide 2.4 mg improves symptoms and weight across diuretic strata and cuts loop diuretic dose in obesity-related HFpEF. PICO summary and expert commentary.
A prespecified pooled secondary analysis of the STEP-HFpEF trials found semaglutide improved symptoms, weight, and exercise capacity consistently across baseline C-reactive protein strata and lowered CRP regardless of weight loss. PICO summary and expert commentary.
A small single-centre study found that adding a long-acting GLP-1 receptor agonist to metformin lowered BMI but did not show a significant between-group glycaemic advantage. PICO summary and expert commentary.
Secondary analysis of the SELECT trial: semaglutide 2.4 mg increased regression to normoglycaemia and reduced progression to diabetes in adults with overweight or obesity and cardiovascular disease, yet did not slow glycaemic progression over time. PICO summary and expert commentary.